T1	Participants 76 127	patients with chronic kidney disease (ESPRIT Trial)
T2	Participants 194 229	patients with mild renal impairment
T3	Participants 386 443	patients who underwent percutaneous coronary intervention
T4	Participants 494 613	patients enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial.
T5	Participants 924 990	Patients with CrCl <60 ml/min were more likely to be older, women,
T6	Participants 614 708	Patients were randomly assigned to placebo or eptifibatide as an adjunct to stent implantation
T7	Participants 1260 1284	patients with lower CrCl
T8	Participants 1645 1680	patients with mild renal impairment
